Dietary Intervention for Migraine Relief
Not yet recruitingNot applicableNCT07360405
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The goal of this clinical trial is to evaluate whether a low-glutamate diet can improve migraine symptoms in adults with migraine and to explore possible biological changes associated with dietary improvement. The study focuses on whether reducing dietary glutamate intake may influence processes involved in migraine, such as brain excitation, inflammation, and oxidative stress. The main questions this study aims to answer are: Does following a low-glutamate diet reduce the number of migraine days and the severity and duration of migraine attacks, and improve quality of life? Are improvements in migraine symptoms associated with changes in blood-based biological markers related to migraine activity? Researchers will compare participants assigned to the low-glutamate diet with participants assigned to a wait-list control group to evaluate differences in migraine outcomes and related biological measures. Participants will: Complete a baseline run-in period while tracking headaches using a daily migraine diary Either follow a low-glutamate dietary intervention or continue their usual diet as part of a wait-list control Complete standardized questionnaires related to migraine symptoms and quality of life Provide blood samples for laboratory analyses Undergo neuroimaging assessments (for a subset of participants)
Study details
- Official title
- Diet-Based Treatment for Migraine Relief
- Conditions
- Interventions
- Behavioral: Dietary training
- Sponsor
- American University
- Collaborators
- Georgetown University
- Start date
- 2026-01
- Primary completion
- 2026-12
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Men and women of all races and ethnicities * Age 18-75 years * Documented diagnosis of chronic or episodic migraine for at least 6 months, based on International Classification of Headache Disorders, 3rd edition (ICHD-III) criteria, defined as: * 8 headache days per month, and * 4 migraine days per month * Migraine onset before age 50 * On a stable medication regimen for at least 1 month prior to enrollment * Willing to maintain stable medications throughout the study * Willing to discontinue supplements during the study period * Women of childbearing potential must be willing to use birth control during the study timeframe Exclusion Criteria: * Current pregnancy, plans to become pregnant during the study timeframe, or current breastfeeding * Current use of medications affecting glutamatergic or gamma-Aminobutyric Acid (GABA) neurotransmission (unless discontinued under physician guidance) * Current use of quarterly injectable migraine preventive medications * Unwillingness to modify dietary intake or to stop alcohol and marijuana use during the study * Substance use disorder within the past year * Diagnosed seizure disorder * Severe asthma requiring past hospitalization
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07360405